No Data
No Data
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing
Jay Lichter, 10% Owner, Director, on June 03, 2024, sold 1,500,000 shares in Janux Therapeutics (JANX) for $82,125,000. Following the Form 4 filing with the SEC, Lichter has control over a total of 3,
Janux Therapeutics(JANX.US) Officer Sells US$45.04 Million in Common Stock
$Janux Therapeutics(JANX.US)$ Officer Reardon Tighe sold 822.72K shares of common stock on Jun 3, 2024 at an average price of $54.75 for a total value of $45.04 million.Source: Announcement What is st
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
JonesTrading analyst Soumit Roy maintains $Janux Therapeutics(JANX.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 26.0% and
Express News | Amarin (AMRN), a constituent stock, fell by 17.91%. Other constituent stocks, Summit Therapeutics Plc., 23Andme Holding Co., and Janux Therapeutics, fell by 17.36%-11.75%. Humacyte also fell by 9.50%. Hutchmed (China) (HCM) rose by 6.49%, Twist Bioscience
Form 144 | Janux Therapeutics(JANX.US) Director Proposes to Sell 7.21 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 3, $Janux Therapeutics(JANX.US)$ Director Avalon BioVentures I, LP intends to sell 131.2K shares of its common stock on Jun 3, with a total market value of approximately $7